# Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2

> **NCT01419639** · PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 10 (actual)

## Conditions studied

- Neurofibromatosis Type II

## Interventions

- **DRUG:** Everolimus (RAD001) , Afinitor®

## Key facts

- **NCT ID:** NCT01419639
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2012-12
- **Final completion:** 2013-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-07-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01419639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01419639, "Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01419639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*